Publications by authors named "R J Hilkert"

Article Synopsis
  • The VICTORIA study found that vericiguat reduced the risk of cardiovascular death or heart failure hospitalization compared to a placebo in patients with heart failure having reduced ejection fraction.
  • The research evaluated how vericiguat impacted the frequency of hospitalizations for heart failure and subsequent mortality, using patient data to analyze various factors.
  • Results showed a slight benefit of vericiguat in patients with lower levels of a specific biomarker (N-terminal pro-B-type natriuretic peptide), but overall, the differences in mortality rates were not significant between the vericiguat and placebo groups.
View Article and Find Full Text PDF

Aims: To explore the associations between social determinants of health and patient-centred outcomes among adults with chronic heart failure with reduced ejection fraction.

Design: Cross-sectional online self-report survey.

Methods: A survey assessing social determinants of health (demographics, socio-economic position, affordability of care and social support) and patient-centred outcomes, including the Kansas City Cardiomyopathy Questionnaire-12 and validated measures of medication adherence, treatment satisfaction, treatment burden and mental health, was completed by 512 adults with chronic heart failure with a reduced ejection fraction between 06 March and 29 June 2020.

View Article and Find Full Text PDF

Background: In January 2021, vericiguat, a soluble guanylate cyclase stimulator, was approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of cardiovascular death and heart failure (HF) hospitalization among patients with a recent worsening HF event based on the VICTORIA (VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.

View Article and Find Full Text PDF

Background: Although a worsening heart failure event (WHFE) is associated with poor outcomes in patients with heart failure with reduced ejection fraction (HFrEF), it is unclear how guideline-directed medical therapy (GDMT) is used in this population compared to those without WHFEs. This study evaluated treatment patterns in patients with HFrEF, both with and without WHFEs.

Methods: A retrospective study using 100% Medicare Fee-For-Service claims identified beneficiaries with HFrEF, stratified by those with and without WHFEs (defined as hospitalization due to HF or outpatient intravenous diuretic use).

View Article and Find Full Text PDF